# Phase 7 — Integration, Validation, and Quality Assurance

## Status

- Milestone: 7.1 integration audit baseline
- Repository revision audited: `d985df3`
- Audit branch: `phase-7/integration-audit`
- Runtime changes: none
- Files moved or deleted: none

## Reports

- `INTEGRATION-AUDIT.md` — repository-wide findings and standardization gaps.
- `SYSTEM-MAP.md` — current agents, artifacts, dependencies, handoffs, and orchestration gap.
- `DEFECT-REGISTER.md` — prioritized defects with evidence and acceptance criteria.
- `MISSING-COMPONENTS.md` — planned or required components not implemented.
- `TESTING-REPORT.md` — checks executed, results, limitations, and required test coverage.
- `RECOMMENDED-CORRECTIONS.md` — minimal additive integration architecture proposed for approval.
- `DEVELOPMENT-BACKLOG.md` — prioritized Phase 7 milestones and deliverables.
- `CHANGE-INVENTORY.md` — exact files created, modified, moved, or deleted in this audit milestone.

## Decision gate

The critical control-plane subset of Milestone 7.2 was authorized after the audit. Its scope and results are recorded in:

- `FINDING-CLASSIFICATION.md` — all 30 findings classified as critical, high, medium, or optional.
- `CORRECTIVE-ACTION-PLAN.md` — critical corrective actions and deferred accuracy work.
- `CRITICAL-TEST-RESULTS.md` — executed tests, results, limitations, and remaining blockers.
- `CRITICAL-CHANGE-INVENTORY.md` — every file created, modified, moved, or deleted.

High-priority accuracy work must not begin until the critical implementation and test results are approved.

The first high-priority milestone was subsequently approved and implemented. Its scope is limited to common-data adapters and release-time accuracy policies:

- `HIGH-PRIORITY-MILESTONE-1.md` — implemented safeguards, adapter coverage, and remaining high-priority work.
- `HIGH-PRIORITY-TEST-RESULTS.md` — automated and static verification evidence.
- `HIGH-PRIORITY-CHANGE-INVENTORY.md` — exact file-level changes.

Excel/P6 generation, full domain handlers, CI, the 39 evaluation cases, and new agents remain paused for separate approval.
